Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Pilot Study to Assess the Safety and Feasibility of Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05497726
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:29.419101+00:00
Published At
2023-11-07T00:00:00+00:00
Record Updated At
2023-11-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Colorectal Neoplasms", "Colon Neoplasm", "Sentinel Lymph Node", "Fluorescence"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-11-07"
protocolSection.identificationModule.nctId
"NCT05497726"
protocolSection.identificationModule.officialTitle
"Pilot Study to Assess the Safety and Feasibility of Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW."
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Colorectal Neoplasms (protocolSection.conditionsModule.conditions)
  • Colon Neoplasm (protocolSection.conditionsModule.conditions)
  • Sentinel Lymph Node (protocolSection.conditionsModule.conditions)
  • Fluorescence (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.